Structure via PubChem · Public domain (PubChem)
anacetrapib
Sign in to saveAlso known as MK-0859
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
In the Vinony graph
Within Vinony's link graph, anacetrapib is referenced by 94 other articles, and connects out to liver, blood vessel and digital object identifier.
Vinony files it under 2-Oxazolidinones, Abandoned drugs and CETP inhibitors.
Its subject is documented across 9 Wikipedia language editions.
Chemical data
- Formula
- C30H25F10NO3
- Molecular weight
- 637.5 g/mol
- IUPAC name
- (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
- SMILES
- C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
- InChIKey
- MZZLGJHLQGUVPN-HAWMADMCSA-N
- XLogP
- 8.8
- Polar surface area
- 38.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 13
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Hypercholesterolemia, Disorder of lipid metabolism, familial hypercholesterolemia, coronary artery disease
via ChEMBL · EBI
Research
268 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 637.167476
Show 3 more facts
- chemical formula
- C₃₀H₂₅F₁₀NO₃
- isomeric SMILES
- C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
- canonical SMILES
- CC1C(OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
4 sectionsContents
- Evidence
- See also
- References
- Further reading
{{chembox | Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1= |Section2= |Section3= }} Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
==Evidence== In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.
Excerpted from Wikipedia’s “anacetrapib” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0